gdc
FDA Approvals, News & UpdatesLung CancerNewsworthy

Imfinzi First Drug Approved to Reduce Cancer Progression in Stage III Lung Cancer

November 2018 Volume 4 – Lung Cancer

In February 2018, the FDA approved Imfinzi (durvalumab; from AstraZeneca), a PD-L1 inhibitor, for the treatment of patients with stage III non–small-cell lung cancer (NSCLC) that cannot be removed by surgery (unresectable) and did not progress after chemoradiation.

“This is the first treatment approved for stage III unresectable non-small cell lung cancer to reduce the risk of the cancer progressing, when the cancer has not worsened after chemoradiation,” said Richard Pazdur, MD, Director of the FDA’s Oncology Center of Excellence.

“Although a small number of patients may be cured with the chemoradiation, the cancer may eventually progress. Patients now have an approved therapy that has been shown to keep the cancer from progressing for a longer time after chemoradiation,” Dr Pazdur added.

In clinical trials, patients who received Imfinzi had an average of 16.8 months without cancer progression versus 5.6 months with placebo. The average duration of survival without disease progression was 16.8 months with Imfinzi versus 5.6 months with placebo.

The common side effects associated with Imfinzi in patients with unresectable stage III NSCLC include cough, fatigue, pneumonitis, upper respiratory tract infections, dyspnea, and rash.

Recommended For You
Breast CancerFDA Approvals, News & UpdatesImmunotherapy
First Immunotherapy Approved for Patients with Advanced or Metastatic Triple-Negative Breast Cancer Expressing PD-L1
In March 2019, the FDA approved Tecentriq (atezolizumab), a PD-L1 inhibitor, in combination with Abraxane (paclitaxel protein-bound), for use in adults with locally advanced or metastatic triple-negative breast cancer whose tumors cannot be removed by surgery and express PD-L1, as identified by an FDA-approved test. This is the first FDA-approved immunotherapy for patients with advanced or metastatic triple-negative breast cancer.
FDA Approvals, News & UpdatesGastric Cancer
Lonsurf Approved for Metastatic Gastric or Gastroesophageal Junction Cancer
In February 2019, the FDA approved Lonsurf for the treatment of patients with metastatic gastric (stomach) cancer or gastroesophageal junction adenocarcinoma. This drug was previously approved only for patients with metastatic colorectal cancer.
Last modified: December 11, 2018

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country